Internal medicine

Surgery

Refractory (planetary science)

Oncology

Chemotherapy

Brentuximab vedotin

Chemotherapy regimen

Lymphoma

Rituximab

Salvage therapy

Regimen

Bendamustine

Hodgkin lymphoma

Medicine

Biology

Astrobiology

Blood

Key Points The outpatient BV and bendamustine regimen is highly active as first salvage therapy in relapsed/refractory HL, with manageable toxicity. The CR rate of 73.6% exceeded those reported for standard chemotherapy regimens, and post-ASCT outcomes generally appeared excellent.

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma